2014-16年抗生素耐药性调查(SOAR)在保加利亚、罗马尼亚、塞尔维亚和克罗地亚的结果
该研究测定了2014-16年保加利亚、罗马尼亚、塞尔维亚和克罗地亚分离的肺炎链球菌(n=573)和流感嗜血杆菌(n=345)的抗生素敏感性。结果显示肺炎链球菌对青霉素和大环内酯类敏感性在罗马尼亚和塞尔维亚最低、保加利亚最高;流感嗜血杆菌敏感性较高且国家间差异较小。不同折点下敏感性差异大,作者认为应协调折点并监测当地耐药模式。
要点
- 肺炎链球菌对青霉素(CLSI口服或EUCAST)敏感性:罗马尼亚22.3%、塞尔维亚21.8%、克罗地亚57%、保加利亚86.6%。
- 肺炎链球菌对大环内酯类(CLSI/EUCAST)敏感性低:罗马尼亚约28%、塞尔维亚34.5%、克罗地亚55.9%、保加利亚约75%。
- 流感嗜血杆菌对阿莫西林/克拉维酸、阿奇霉素、头孢呋辛、头孢曲松和氟喹诺酮类CLSI敏感性≥98%,但阿奇霉素和头孢呋辛EUCAST敏感性仅0%-1%。
核心结论
- 不同折点下抗菌药物敏感性差异大,使临床医生难以解读耐药数据,应努力协调折点。
- 四个邻国间的差异表明需要监测并发布国家和当地耐药模式。
- 这些发现为选择合适抗菌药物治疗肺炎链球菌和流感嗜血杆菌提供了关键信息。
研究设计与样本
- 研究测定了2014-16年从保加利亚、罗马尼亚、塞尔维亚和克罗地亚收集的肺炎链球菌(n=573)和流感嗜血杆菌(n=345)分离株的抗生素敏感性。
- MIC通过CLSI肉汤微量稀释法测定,敏感性采用CLSI、EUCAST和药代动力学/药效学(PK/PD)折点评估。
主要发现
- 肺炎链球菌敏感性一般在罗马尼亚和塞尔维亚最低、保加利亚最高;对青霉素(CLSI口服或EUCAST)敏感性在罗马尼亚为22.3%、塞尔维亚为21.8%、克罗地亚为57%、保加利亚为86.6%。
- 肺炎链球菌对大环内酯类(CLSI/EUCAST折点)敏感性在罗马尼亚和塞尔维亚低(分别约28%和34.5%),克罗地亚较高(55.9%),保加利亚最高(约75%)。
- 仅氟喹诺酮类对四国所有分离株均有活性;流感嗜血杆菌敏感性较高且国家间差异较小。
- 流感嗜血杆菌按CLSI标准对阿莫西林/克拉维酸、阿奇霉素、头孢呋辛、头孢曲松和氟喹诺酮类敏感性在所有国家≥98%;氨苄西林敏感性从罗马尼亚85.3%到保加利亚100%。
- 按CLSI标准阿奇霉素和头孢呋辛敏感性在四国均≥98%,但按EUCAST标准为0%-1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine antibiotic susceptibility of isolates of Streptococcus pneumoniae (n = 573) and Haemophilus influenzae (n = 345) collected in 2014-16 from Bulgaria, Romania, Serbia and Croatia. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: Among S. pneumoniae, susceptibility was generally lowest in Romania and Serbia and highest in Bulgaria. Rates of susceptibility to penicillin (CLSI oral or EUCAST) were 22.3% and 21.8% in Romania and Serbia respectively, 57% in Croatia and 86.6% in Bulgaria. Similarly, macrolide susceptibility using CLSI/EUCAST breakpoints was low in Romania and Serbia (∼28% and 34.5%, respectively), higher in Croatia (55.9%) and highest in Bulgaria (∼75%). Only fluoroquinolones were active against all isolates in all four countries. Susceptibility was higher and variability across countries less pronounced for H. influenzae. Susceptibility by CLSI criteria to amoxicillin/clavulanic acid, azithromycin, cefuroxime, ceftriaxone and fluoroquinolones was ≥98% in all countries. Ampicillin susceptibility ranged from 85.3% in Romania to 100% in Bulgaria. Much greater variability was seen across breakpoints. Susceptibility to azithromycin and cefuroxime using CLSI criteria was ≥98% in all four countries, but was 0%-1% by EUCAST criteria. CONCLUSIONS: The variability in antimicrobial susceptibility using different breakpoints makes it difficult for clinicians to interpret antimicrobial resistance data, and efforts should be made to harmonize breakpoints. The variability found across the four neighbouring countries demonstrates the need to monitor and publish national and local resistance patterns. These findings provide information critical for the selection of appropriate antimicrobial agents for the treatment of S. pneumoniae and H. influenzae.
引用
- Torumkuney D, Nica M, Nistor I, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Bulgaria, Romania, Serbia and Croatia. J Antimicrob Chemother. 2018. PMID: 29659882. doi:10.1093/jac/dky066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。